Idogen AB (OSTO:IDOGEN) Beginning Cash Position: kr5.31 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IDOGEN Idogen AB OSTO:IDOGEN
21 GF Score
Price kr0.12
View Full Analysis

What is Idogen AB Beginning Cash Position?

Idogen AB OSTO:IDOGEN 21 Beginning Cash Position is kr5.31 Mil as of Mar. 2023. GuruFocus rates OSTO:IDOGEN with a GF Score™ of 21/100.

Idogen AB's Beginning Cash Position for the quarter that ended in Mar. 2023 was kr5.31 Mil.

Idogen AB's quarterly Beginning Cash Position declined from Sep. 2022 (kr26.94 Mil) to Dec. 2022 (kr16.74 Mil) and declined from Dec. 2022 (kr16.74 Mil) to Mar. 2023 (kr5.31 Mil).

Idogen AB's annual Beginning Cash Position increased from Dec. 2020 (kr26.01 Mil) to Dec. 2021 (kr47.04 Mil) but then declined from Dec. 2021 (kr47.04 Mil) to Dec. 2022 (kr15.56 Mil).

Idogen AB Beginning Cash Position Related Terms

Idogen AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Idogen AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idogen AB Beginning Cash Position Chart

Idogen AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 36.94 61.61 26.01 47.04 15.56

Idogen AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.56 38.63 26.94 16.74 5.31
OSTO:IDOGEN
21GF Score
Idogen AB OSTO:IDOGEN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idogen AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr5.31 Mil mean?
Idogen AB (OSTO:IDOGEN) has a Beginning Cash Position of kr5.31 Mil as of Mar. 2023. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Idogen AB and its competitors.
Is Idogen AB's Beginning Cash Position too high?
Idogen AB's current Beginning Cash Position is kr5.31 Mil. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's Beginning Cash Position compare to REGN and VRTX?
Idogen AB's Beginning Cash Position of kr5.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Idogen AB and its competitors. Idogen AB's current Beginning Cash Position is kr5.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current Beginning Cash Position of kr5.31 Mil. The current Beginning Cash Position is kr5.31 Mil. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current Beginning Cash Position is kr5.31 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Idogen AB Business Description

Address Medicon Village, Scheelevagen 2, Lund, SWE, 223 81
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score

Get the complete analysis for OSTO:IDOGEN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price